Success Metrics

Active Trials
7(100%)

Phase Distribution

Ph phase_1
4
57%
Ph phase_2
2
29%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

7

all time

Status Distribution
Active(7)

Detailed Status

Active, not recruiting4
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
7
Active
7
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

recruiting343%
active_not_recruiting457%

Recent Activity

7 active trials
Showing 5 of 7
active_not_recruitingphase_1

Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis

NCT06475495
active_not_recruitingphase_1

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

NCT06152172
recruiting

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

NCT07403188
recruitingphase_2

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT06193889
active_not_recruitingphase_1

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

NCT06400303
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06475495Phase 1

Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis

Active Not Recruiting
NCT06152172Phase 1

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

Active Not Recruiting
NCT07403188

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Recruiting
NCT06193889Phase 2

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Recruiting
NCT06400303Phase 1

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Active Not Recruiting
NCT06298019Phase 1

Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis

Recruiting
NCT06384976Phase 2

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Active Not Recruiting

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7